Featured Editorial

1. RNA Delivery Technologies: Industrial Applications And Emerging Innovations 2/10/2026

   RNA delivery is moving from breakthrough to backbone. This review examines how LNPs and emerging carriers are reshaping scalability, targeting, manufacturing, and real-world deployment of RNA therapeutics.

2. Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones 2/9/2026

   For the next-generation cell and gene therapies, we must rethink design and controls, and we must reframe the problem from modality to architecture.

3. 4 Opportunities For Advancing Drug Delivery 2/3/2026

   In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies. 

4. In Vivo's Biggest Threat — Comparison To Old Models 1/23/2026

   In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.

5. The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs 1/15/2026

   The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).

6. Conducting A Medical Device Stability Study: A Practical Guide 1/7/2026

   Stability studies measure how medical devices respond to environmental stresses such as temperature, humidity, light, and time. Let's take a closer look at designing and conducting a stability study.

7. Nanotechnology Drug Delivery: A Market Overview 1/6/2026

   New market research reveals the scientific, geopolitical, and business trends driving growth in the nanotechnology drug delivery market.

8. Combination: The Drug Delivery Word Of The Year For 2026 12/30/2025

   In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.

9. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

   By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

10. Electronic Drug Delivery Devices Market: Advancing Smart, Connected Healthcare 12/19/2025

    What is factoring into market growth for electronic drug delivery devices and why? New market research shares key insights.